GamaMabs Pharma SA Announces Two Scientific Communications On Its AMHR2 Project

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TOULOUSE, France--(BUSINESS WIRE)--GamaMabs Pharma, which holds exclusive rights on 12G4 and 3C23K monoclonal antibodies targeting AMHR2 / MISR2, announces two communications on these antibodies.

The article, “The human Müllerian inhibiting substance type 2 receptor as immunotherapy target for Ovarian Cancer: validation using the mAb 12G4”, N Kersual / I Navarro-Teulon, is published in mAbs (Vol. 6, Issue 5, 2014) by IRCM and ICM teams (France). The article shows that the 12G4 murine antibody targeting AMHR2 increases the survival of mice bearing ovarian tumor and confirms AMHR2 as a promising target for ovarian cancer treatment.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news